http://rdf.ncbi.nlm.nih.gov/pubchem/patent/MX-2017009913-A
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_f6bbf371c1d415d1eaa0093649975a7d |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-4858 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-19 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P7-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P7-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K33-36 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-20 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-26 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-48 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K33-36 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-48 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-16 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 |
| filingDate | 2016-02-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c6b2b8eb8571b6aa5e3020a2e8fb6671 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_705d2343b158d1fbf1a29db5fc539799 |
| publicationDate | 2018-08-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | MX-2017009913-A |
| titleOfInvention | LIOFILIZED COMPOSITIONS OF HIGH AREA AREA THAT INCLUDE ARSENIC FOR ORAL ADMINISTRATION IN PATIENTS. |
| abstract | The present invention relates to the treatment of malignancies such as tumors or cancers by oral administration of lyophilized compositions comprising arsenic to a subject in such need. Malignancies include different hematological malignancies, such as acute myeloid leukemia (AML) including acute promyelocytic leukemia (APL), myelodysplastic syndrome (MDS), multiple myeloma (MM) and solid lymphomas and tumors including glioblastoma multiforme and breast cancer. Arsenic treatment has shown to be very promising in the treatment of several cancers but requires daily intravenous (IV) administration. This invention relates to a novel formulation comprising a lyophilized composition comprising arsenic. As a result, the formulation facilitates a systemic bioavailability comparable to that of the intravenous (IV) administration of arsenic trioxide that is currently practiced. The present invention also relates to a method for lyophilizing arsenic trioxide, preparing the oral formulation comprising lyophilized compositions comprising arsenic, and a method for treating a subject with malignancies using the oral formulation. |
| priorityDate | 2015-02-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 34.